| Autor: |
Ghimire, Samiksha, Maharjan, Bhagwan, Jongedijk, Erwin M, Kosterink, Jos G W, Ghimire, Gokarna R, Touw, Daan J, van der Werf, Tjip S, Shrestha, Bhabana, Alffenaar, Jan-Willem C |
| Přispěvatelé: |
Guided Treatment in Optimal Selected Cancer Patients (GUTS), Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Targeted Gynaecologic Oncology (TARGON), PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute for Asthma and COPD (GRIAC), Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Pharmaceutical Analysis, Microbes in Health and Disease (MHD), Medicinal Chemistry and Bioanalysis (MCB) |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Antimicrobial Agents and Chemotherapy, 63(5):e02379-18. AMER SOC MICROBIOLOGY |
| ISSN: |
1098-6596 |
| Popis: |
Saliva may be a useful alternative matrix for monitoring levofloxacin concentrations in multi-drug resistant TB patients. The objectives of this study were: a) to evaluate the correlation between plasma and salivary Lfx concentrations in MDR-TB patients; and b) to gauge the possibility of using saliva as an alternative sampling matrix for therapeutic drug monitoring of Lfx in TB endemic areas. This was a prospective pharmacokinetic study that enrolled MDR-TB patients receiving levofloxacin (Lfx; 750-1000mg once daily dosing) under standardized treatment regimen in Nepal. Paired blood and saliva samples were collected at steady state. Lfx concentrations were quantified using liquid chromatography- tandem mass spectrometry. Pharmacokinetic parameters were calculated using non-compartmental kinetics. Lfx drug exposure was evaluated in 23 MDR-TB patients. During the first month, the median (IQR) area under the concentration-time curve (AUC0-24) was 67.09 (53.93-98.37) mg*h/L in saliva and 99.91 (76.80-129.70) mg*h/L in plasma, and the saliva plasma (S/P) ratio was 0.69 (0.53-0.99). Similarly, during the second month, the median (IQR) AUC0-24 was 75.63 (61.45-125.5) mg*h/L in saliva and 102.7 (84.46-131.9) mg*h/L in plasma with a S/P ratio of 0.73 (0.66-1.18). Furthermore, large inter-and intra-individual variabilities in Lfx concentrations were observed. This study could not demonstrate a strong correlation between plasma and saliva Lfx levels. Despite a good Lfx penetration in saliva, the variability in individual saliva-to-plasma ratios limits the use of saliva as a valid substitute for plasma. Nevertheless, saliva could be useful in semi-quantitatively predicting Lfx plasma levels. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
